News
Sarepta Therapeutics (NASDAQ:SRPT) shares dropped sharply premarket on Monday before paring losses as Barclays revised its ...
2don MSN
The U.S. Food and Drug Administration said on Friday it was investigating the death of an eight-year-old boy who received ...
US regulators are investigating the death of an 8-year-old boy in Brazil who received Sarepta Therapeutics Inc.’s Elevidys.
In its own communique issued shortly after the FDA’s, Sarepta elaborated on the situation and confirmed a Roche statement to ...
The U.S. Food and Drug Administration (FDA) announced on Friday, after market close, that it is investigating the death of an ...
Sarepta Therapeutics Inc. (NASDAQ:SRPT) is one of the most undervalued stocks to buy and hold for 3 years. On July 22, BMO ...
Brazilian authorities said the death was unlikely to have been caused by Elevidys and was instead more in line with severe ...
Sarepta Therapeutics now trades at book value with strong cash and cost-cutting plans, while ELEVIDYS may regain broader use.
The US Food and Drug Administration (FDA) issued a press release late Friday announcing an investigation into the death of an ...
The Trump FDA tries to kill a therapy that has helped boys with a deadly diagnosis.
The Food and Drug Administration is investigating Sarepta’s gene therapy products following reports of a third death from acute liver failure.
The European Medicines Agency determined testing failed to prove Elevidys’ benefit and issued a negative opinion that could ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results